Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, estetrol / drospirenone (Drovelis®) cannot be endorsed for use within NHS Wales for use as an oral contraceptive. |
||
|
||
Medicine details |
||
| Medicine name | estetrol / drospirenone (Drovelis®) | |
| Formulation | 14.2 mg / 3 mg film-coated tablet | |
| Reference number | 4336 | |
| Indication | For oral contraception. The decision to prescribe the medicine should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with the medicine compares with other combined hormonal contraceptives (CHCs) |
|
| Company | Gedeon Richter (UK) Ltd | |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/11/2021 | |